1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Legal & IP

Ellume Faces Class-Action Suit After Class I Recall Of COVID-19 Tests

 
• By Elizabeth Orr

The lawsuit, filed in Maryland federal court, says Ellume should’ve offered refunds to people who bought later-recalled COVID-19 tests from the company.

Ellume Health's COVID-19 At Home Test is the first such test authorized over-the-counter by the FDA.
• Source: Ellume Health

Consumers are suing Ellume after the diagnostics firm refused to give refunds to purchasers of later-recalled COVID-19 tests.

The class-action suit, filed in Maryland District Court, alleges that the money for the recalled tests kept by Ellume qualifies as unjust enrichment. It asks for financial compensation “in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Policy & Regulation

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

Plans For Specific EU Orphan And Pediatric Device Expert Panel Need To Go Further

 
• By Amanda Maxwell

Moves are at last underway for a more specific focus on orphan and pediatric devices. They are a start; but experts are calling for more to support this sector.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.